DAWN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Day One Biopharmaceuticals Inc (DAWN) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is experiencing negative price momentum, weak financial performance, and lacks significant positive catalysts or trading signals. It is better to wait for clearer signs of recovery or growth before considering an investment.
The technical indicators suggest a bearish trend. The MACD is negatively expanding, RSI is neutral at 43.329, and moving averages are converging, indicating no clear trend reversal. The stock is trading below the pivot level of 11.157, with key support at 10.512 and resistance at 11.803.
No significant positive catalysts identified. The stock has a 6% chance of increasing in the next month based on historical patterns.
The stock price has been declining, with a -2.05% regular market change and a -1.86% post-market change. Financial performance in Q3 2025 showed significant declines in revenue (-57.56% YoY), net income (-153.26% YoY), and EPS (-150.00% YoY). No recent news or significant insider or hedge fund activity.
In Q3 2025, the company reported a revenue drop to $39.8M (-57.56% YoY), net income of -$19.73M (-153.26% YoY), EPS of -0.19 (-150.00% YoY), and a gross margin drop to 88.74 (-9.73% YoY). These metrics indicate weak financial health and declining growth trends.
TD Cowen recently lowered the price target from $34 to $24 while maintaining a Buy rating. This reflects reduced optimism about the stock's future performance.
